SCHEMBL5313856

SCHEMBL5313856

CCCCCCCCCNCCCC

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.87
ALDH1A1 P00352 1/20 0.87
EPHX1 P07099 6/20 0.58
ADH1B P00325 2/20 0.57
ADH1C P00326 2/20 0.57
ADH1A P07327 2/20 0.57
ADH7 P40394 2/20 0.57
ADH4 P08319 1/20 0.57
S1PR2 O95136 5/20 0.56
S1PR4 O95977 5/20 0.56
S1PR1 P21453 5/20 0.56
S1PR3 Q99500 5/20 0.56
S1PR5 Q9H228 1/20 0.56
THRB P10828 1/20 0.53
CYP2C19 P33261 2/20 0.53
CYP1A2 P05177 1/20 0.53
SIGMAR1 Q99720 1/20 0.48
MEN1 O00255 1/20 0.47
GLA P06280 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165020 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL4315670 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL8980568 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL8980623 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL6545006 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL25210211 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL5502786 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL5500928 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL21611676 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C
SCHEMBL237903 1.00 TSHR (0.87) TSHRALDH1A1EPHX1ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108779233-A Hardener composition for epoxy resin based coating compositions, method for the preparation and use thereof 湛新奥地利有限公司 2018-11-09 CN claimed
US-11819584-B2 Nucleic acid decontamination methods CEPHEID (US) 2023-11-21 US disclosed
WO-2023196679-A1 2,3-PYRROLIDINEDIONE CONJUGATES AND METHODS OF USING THEREOF NORTH CAROLINA STATE UNIVERSITY (US) 2023-10-12 WO disclosed
CN-113061722-B Extraction method for separating calcium from low-temperature calcium-containing brine to extract lithium and application of extraction method 湘潭大学 2022-08-09 CN disclosed
CN-111868842-B Conductive paste with stable viscosity over time 株式会社则武 2021-11-19 CN disclosed
CN-113061722-A Extraction method for separating calcium from low-temperature calcium-containing brine to extract lithium and application of extraction method 湘潭大学 2021-07-02 CN disclosed
CN-110669938-B Extraction system for separating magnesium from magnesium-containing brine by using secondary amide/alkyl ketone composite solvent and extracting lithium, extraction method and application thereof 湘潭大学 2021-04-13 CN disclosed
CN-110656249-B Extraction system for separating magnesium from magnesium-containing brine by using secondary amide/alkane composite solvent, extraction method and application thereof 湘潭大学 2021-03-23 CN disclosed
CN-111868842-A Conductive paste with stable viscosity over time 株式会社则武 2020-10-30 CN disclosed
CN-110669938-A Extraction system for separating magnesium from magnesium-containing brine by using secondary amide/alkyl ketone composite solvent and extracting lithium, extraction method and application thereof 湘潭大学 2020-01-10 CN disclosed
US-20110112199-A1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2011-05-12 US disclosed
US-7700771-B2 Heterocyclic compound which may be used as a medicine having p38 MAP kinase inhibitory activity MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-04-20 US disclosed
US-20080200501-A1 NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION GLENMARK PHARMACEUTICALS S.A. (CH) 2008-08-21 US disclosed
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative MSD K.K. (JP) 2008-07-17 US disclosed
CN-101189002-A Methods for modulating macrophage proliferation in ocular disease using polyamine analogs PATHOLOGICA LLC (US) 2008-05-28 CN disclosed
EP-1855663-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION IN OCULAR DISEASE USING POLYAMINE ANALOGS Pathologica, LLC. (US) 2007-11-21 EP disclosed
WO-2006091522-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION IN OCULAR DISEASE USING POLYAMINE ANALOGS PATHOLOGICA, LLC. (US) 2006-08-31 WO disclosed
CN-1606694-A Methods for monitoring and treating amyotrophic lateral sclerosis SLIL BIOMEDICAL CORP (US) 2005-04-13 CN disclosed
CN-1099388-A Heteroatom-bearing ligands and metal complexes thereof BRISTOL MYERS SQIBB COMPANY (US) 1995-03-01 CN disclosed
US-4992150-A Telomer with alpha-olefin;oil and fuel additive NIPPON OIL CO, LTD. (JP) 1991-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative HRH3, HRH4, HRH2 TSHR 120/4885ALDH1A1 1954/4885EPHX1 907/4885
US-20080200501-A1 NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION CNR2, CNR1, OPRL1 TSHR 1795/4885ALDH1A1 4441/4885EPHX1 1904/4885
US-20110112199-A1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE BPGM, PYGB, EDNRB TSHR 1498/4885ALDH1A1 1462/4885EPHX1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.